
    
      HH2710 is developed by Shanghai Haihe Pharmaceutical Co., Ltd. HH2710 is a highly potent,
      selective, reversible, ATP-competitive ERK1/2 inhibitor. This is a first-in-human study of
      HH2710 and is designed as an open-label, multicenter, Phase I/II study which is composed of a
      Phase I dose escalation and dose expansion stage and a Phase II dose extension stage.
    
  